Targets › MENIN
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: the race on MENIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Soochow University | BY002 Menin inhibitor targeting KMT2A-rearranged and NPM1-mutant acute leukemia | KMT2A, MENIN | Phase 1 | Acute Leukemia | Mar 2027 |
Acute Leukemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.